Study of Dalantercept in Patients With Squamous Cell Carcinoma of the Head and Neck
NCT01458392
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
46
Enrollment
INDUSTRY
Sponsor class
Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
BIOLOGICAL:
Dalantercept
Sponsor
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA